Raymond James Financial’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$842K Sell
34,451
-4,295
-11% -$120K ﹤0.01% 4162
2026
Q2
$1.33M Buy
38,746
+6,183
+19% +$187K ﹤0.01% 3784
2026
Q1
$776K Buy
32,563
+4,448
+16% +$123K ﹤0.01% 4046
2025
Q4
$779K Buy
28,115
+788
+3% +$20.1K ﹤0.01% 3952
2025
Q3
$663K Buy
27,327
+5,442
+25% +$108K ﹤0.01% 3945
2025
Q2
$372K Sell
21,885
-4,421
-17% -$77K ﹤0.01% 4176
2025
Q1
$514K Sell
26,306
-2,022
-7% -$53K ﹤0.01% 3927
2024
Q4
$703K Buy
+28,328
New +$723K ﹤0.01% 3689

Other funds holding BEAM

Raymond James Financial's BEAM Position: Q3 2026 in Review

Raymond James Financial reduced its Beam Therapeutics (BEAM) stake by 11% in Q3 2026, selling an estimated $120K and leaving 34,451 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #4162.

Raymond James Financial first reported a position in BEAM in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.33M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Raymond James Financial held 34,451 shares of Beam Therapeutics worth $842K as of Q3 2026.
  • Raymond James Financial sold 4,295 Beam Therapeutics shares in Q3 2026, an estimated $120K.
  • Beam Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4162 holding.
  • Raymond James Financial first reported a position in Beam Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Beam Therapeutics position peaked at $1.33M in Q2 2026.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.